Coherus Oncology Inc
CHRS
Company Profile
Business description
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
Contact
333 Twin Dolphin Drive
Suite 600
Redwood CityCA94065
USAT: +1 650 649-3530
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
221
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,741.90 | 26.70 | -0.30% |
| CAC 40 | 7,804.87 | 14.60 | 0.19% |
| DAX 40 | 24,304.46 | 19.12 | -0.08% |
| Dow JONES (US) | 42,762.87 | 443.13 | 1.05% |
| FTSE 100 | 8,837.91 | 26.87 | 0.30% |
| HKSE | 23,792.54 | 114.43 | -0.48% |
| NASDAQ | 19,529.95 | 231.51 | 1.20% |
| Nikkei 225 | 37,741.61 | 187.12 | 0.50% |
| NZX 50 Index | 12,563.48 | 13.67 | -0.11% |
| S&P 500 | 6,000.36 | 61.06 | 1.03% |
| S&P/ASX 200 | 8,515.70 | 23.20 | -0.27% |
| SSE Composite Index | 3,385.36 | 1.26 | 0.04% |